EARTS Study 1999.

Methods	Study design: parallel RCT Study duration: not reported Study follow‐up: 1 year
Participants	Country: Finland/Sweden/Norway/Germany Setting: multicentre (10) Inclusion criteria: adult DD kidney transplant recipients Number: treatment group (131); control group (131) Mean age, range (years): treatment group (48.0, 21 to 78); control group (45.1, 16 to 77) Sex (M/F): treatment group (83/48); control group (89/42) Exclusion criteria: history of malignancy; previous exposure to murine antibodies; active infection; ongoing pregnancy
Interventions	Treatment group Enlimomab: 160 mg IV 3 hours prior to transplant, then 40 mg/d for 5 days CSA/AZA/PRED per local protocol Placebo CSA/AZA/PRED per local protocol 17 patients across both groups got ATG for DGF
Outcomes	Death Graft loss Acute rejection ‐ at 3 months and 1 year DGF Infections Malignancy
Notes	Funding source: not reported
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	'Performed in blocks of 6 to ensure balanced distribution of treatment per centre'
Allocation concealment (selection bias)	Low risk	Central allocation
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Double‐blinded
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Double‐blinded; pathologist reviewing biopsies for suspected acute rejection was also blinded
Incomplete outcome data (attrition bias) All outcomes	Low risk	All patient outcome data reported
Selective reporting (reporting bias)	Unclear risk	All expected outcomes reported
Other bias	Unclear risk	Appears free from other bias but funding source not declared